{"url":"https://lda.senate.gov/api/v1/filings/38e57644-4209-49dc-80ca-e754a5c74524/","filing_uuid":"38e57644-4209-49dc-80ca-e754a5c74524","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2024,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/38e57644-4209-49dc-80ca-e754a5c74524/print/","filing_document_content_type":"text/html","income":null,"expenses":"240000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Jennie Unger Skelton","dt_posted":"2024-04-19T16:49:18-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"c/o 28 Liberty Ship Way, Suite 2815","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Sausalito","registrant_state":"CA","registrant_zip":"94965","registrant":{"id":401103510,"url":"https://lda.senate.gov/api/v1/registrants/401103510/","house_registrant_id":null,"name":"SAREPTA THERAPEUTICS, INC.","description":"Biopharmaceutical company","address_1":"c/o 28 Liberty Ship Way, Suite 2815","address_2":null,"address_3":null,"address_4":null,"city":"Sausalito","state":"CA","state_display":"California","zip":"94965","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JENNIE UNGER SKELTON","contact_telephone":"+1 415-903-2800","dt_updated":"2026-07-23T16:08:48.090815-04:00"},"client":{"id":199232,"url":"https://lda.senate.gov/api/v1/clients/199232/","client_id":12,"name":"SAREPTA THERAPEUTICS, INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2014-12-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to patient access to treatments Issues related to rare diseases, including Duchenne Muscular Dystrophy Issues related to newborn screening for rare diseases Issues related to scientific innovation in healthcare, including gene therapies Public Law 117-169, Inflation Reduction Act of 2022; Provisions related to prescription drugs","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":139377,"prefix":"mr","prefix_display":"MR.","first_name":"KIP","nickname":null,"middle_name":null,"last_name":"PAYNE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax issues related to research and development","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":139377,"prefix":"mr","prefix_display":"MR.","first_name":"KIP","nickname":null,"middle_name":null,"last_name":"PAYNE","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"SCI","general_issue_code_display":"Science/Technology","description":"Issues related to artificial intelligence and data governance","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":139377,"prefix":"mr","prefix_display":"MR.","first_name":"KIP","nickname":null,"middle_name":null,"last_name":"PAYNE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}